{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:01:00Z","timestamp":1780977660926,"version":"3.54.1"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003970","name":"Isfahan University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003970","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.msard.2026.107265","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T15:45:47Z","timestamp":1779551147000},"page":"107265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Uncovering the role of microRNAs in response to interferon-beta therapy among multiple sclerosis patients: A systematic review"],"prefix":"10.1016","volume":"111","author":[{"given":"Mitra","family":"Pourseirafi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Reza","family":"Mousavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoosha","family":"Niazmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasimeh","family":"Vatandoost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoor","family":"Salehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.msard.2026.107265_bib0001","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1007\/s10528-024-10909-z","article-title":"Evaluating the serum level of ACTH and investigating the expression of MiR-26a, MiR-34a, MiR-155-5p, and MiR-146a in the peripheral blood cells of Multiple sclerosis patients","volume":"63","author":"Al-Dahimavi","year":"2025","journal-title":"Biochem. Genet."},{"key":"10.1016\/j.msard.2026.107265_bib0002","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.3389\/fimmu.2019.03125","article-title":"Differentiation of pathogenic Th17 cells is negatively regulated by Let-7 microRNAs in a mouse model of multiple sclerosis","volume":"10","author":"Angelou","year":"2020","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.msard.2026.107265_bib0003","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/s41577-022-00718-z","article-title":"The immunology of multiple sclerosis","volume":"22","author":"Attfield","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.msard.2026.107265_bib0004","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S1474-4422(21)00063-6","article-title":"Cellular immunology of relapsing multiple sclerosis: interactions, checks, and balances","volume":"20","author":"Bar-Or","year":"2021","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.msard.2026.107265_bib0005","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-23723-7","article-title":"MiR-27a as a diagnostic biomarker and potential therapeutic target in systemic sclerosis","volume":"12","author":"Bayati","year":"2022","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.msard.2026.107265_bib0006","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23063383","article-title":"Emerging biomarkers of multiple sclerosis in the blood and the CSF: a focus on neurofilaments and therapeutic considerations","volume":"23","author":"Biernacki","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.msard.2026.107265_bib0007","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/bioinformatics\/btt019","article-title":"CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data","volume":"29","author":"Bindea","year":"2013","journal-title":"Bioinformatics"},{"issue":"8","key":"10.1016\/j.msard.2026.107265_bib0008","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/bioinformatics\/btp101","article-title":"ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks","volume":"25","author":"Bindea","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1016\/j.msard.2026.107265_bib0009","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.3390\/biom13081204","article-title":"CXCL10 Is associated with increased cerebrospinal fluid immune cell infiltration and disease duration in multiple sclerosis","volume":"13","author":"Blandford","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.msard.2026.107265_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-1-2","article-title":"The nuts and bolts of PROSPERO: an international prospective register of systematic reviews","volume":"1","author":"Booth","year":"2012","journal-title":"Syst. Rev."},{"issue":"4","key":"10.1016\/j.msard.2026.107265_bib0011","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1186\/1752-0509-8-S4-S11","article-title":"cytoHubba: identifying hub objects and sub-networks from complex interactome","volume":"8","author":"Chin","year":"2014","journal-title":"BMC Syst. Biol."},{"issue":"2","key":"10.1016\/j.msard.2026.107265_bib0012","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021448","article-title":"A comprehensive exploration of the transcriptomic landscape in Multiple sclerosis: a systematic review","volume":"24","author":"Chiricosta","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.msard.2026.107265_bib0013","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1212\/WNL.0000000000012323","article-title":"Secondary progressive multiple sclerosis: new insights","volume":"97","author":"Cree","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107265_bib0014","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1755-8794-7-26","article-title":"Small non-coding RNA signature in multiple sclerosis patients after treatment with interferon-\u03b2","volume":"7","author":"De Felice","year":"2014","journal-title":"BMC Med. Genom."},{"issue":"6","key":"10.1016\/j.msard.2026.107265_bib0015","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41582-020-0355-1","article-title":"Treatment and management of cognitive dysfunction in patients with multiple sclerosis","volume":"16","author":"DeLuca","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2026.107265_bib0016","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4274\/csmedj.galenos.2022.2022-11-11","article-title":"Expanded disability status scale (EDSS) in multiple sclerosis","volume":"2","author":"Demir","year":"2022","journal-title":"Cam Sakura Med. J."},{"key":"10.1016\/j.msard.2026.107265_bib0017","article-title":"The Joanna Briggs Institute approach for systematic reviews","volume":"26","author":"dos Santos","year":"2018","journal-title":"Rev. Lat. Am. Enferm."},{"issue":"12","key":"10.1016\/j.msard.2026.107265_bib0018","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1038\/ni.1798","article-title":"MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis","volume":"10","author":"Du","year":"2009","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.msard.2026.107265_bib0019","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s12031-016-0851-3","article-title":"miR-145 and miR20a-5p potentially mediate pleiotropic effects of interferon-beta through mitogen-activated protein kinase signaling pathway in multiple sclerosis patients","volume":"61","author":"Ehtesham","year":"2017","journal-title":"J. Mol. Neurosci."},{"issue":"1","key":"10.1016\/j.msard.2026.107265_bib0020","first-page":"92","article-title":"Comparison of the expression of miR-326 between interferon beta responders and non-responders in relapsing-remitting multiple sclerosis","volume":"22","author":"Fattahi","year":"2020","journal-title":"Cell J."},{"key":"10.1016\/j.msard.2026.107265_bib0021","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.msard.2019.07.034","article-title":"MicroRNA-29b variants and MxA expression change during interferon beta therapy in patients with relapsing-remitting multiple sclerosis","volume":"35","author":"Fattahi","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107265_bib0022","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ebiom.2019.09.059","article-title":"Interferon-\u03b2 corrects massive gene dysregulation in multiple sclerosis: short-term and long-term effects on immune regulation and neuroprotection","volume":"49","author":"Feng","year":"2019","journal-title":"EBioMedicine"},{"issue":"10","key":"10.1016\/j.msard.2026.107265_bib0023","doi-asserted-by":"crossref","first-page":"13227","DOI":"10.3390\/ijms131013227","article-title":"MicroRNAs as active players in the pathogenesis of multiple sclerosis","volume":"13","author":"Fenoglio","year":"2012","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.msard.2026.107265_bib0024","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1176\/appi.ajp.2010.10040484","article-title":"Association of mouse Dlg4 (PSD-95) gene deletion and human DLG4 gene variation with phenotypes relevant to autism spectrum disorders and Williams\u2019 syndrome","volume":"167","author":"Feyder","year":"2010","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.msard.2026.107265_bib0025","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7224\/1537-2073.2018-063","article-title":"Interferons in the treatment of multiple sclerosis: a clinical efficacy, safety, and tolerability update","volume":"22","author":"Filipi","year":"2020","journal-title":"Int. J. MS Care"},{"issue":"3","key":"10.1016\/j.msard.2026.107265_bib0026","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaneurol.2020.4689","article-title":"Diagnosis of progressive multiple sclerosis from the imaging perspective: a review","volume":"78","author":"Filippi","year":"2021","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.msard.2026.107265_bib0027","doi-asserted-by":"crossref","first-page":"4984","DOI":"10.1038\/s41598-018-22676-0","article-title":"Profiling walking dysfunction in multiple sclerosis: characterisation, classification and progression over time","volume":"8","author":"Filli","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.msard.2026.107265_bib0028","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.cca.2021.01.020","article-title":"MicroRNA in multiple sclerosis","volume":"516","author":"Gao","year":"2021","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.msard.2026.107265_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173127","article-title":"A comprehensive review of non-coding RNAs functions in multiple sclerosis","volume":"879","author":"Ghafouri-Fard","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.msard.2026.107265_bib0030","first-page":"29","article-title":"Re-evaluating the use of IFN-\u03b2 and relapsing multiple sclerosis: safety, efficacy and place in therapy","author":"Goldschmidt","year":"2020","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"issue":"9","key":"10.1016\/j.msard.2026.107265_bib0031","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1474-4422(22)00255-1","article-title":"Genetics of multiple sclerosis: lessons from polygenicity","volume":"21","author":"Goris","year":"2022","journal-title":"Lancet Neurol."},{"issue":"8","key":"10.1016\/j.msard.2026.107265_bib0032","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000037297","article-title":"Review of multiple sclerosis: epidemiology, etiology, pathophysiology, and treatment","volume":"103","author":"Haki","year":"2024","journal-title":"Medicine"},{"issue":"2","key":"10.1016\/j.msard.2026.107265_bib0033","first-page":"158","article-title":"The effect of interferon beta and Natalizumab on miR-20b expression in patients with relapsing-remitting multiple sclerosis is potentially mediated by modulation of the Jak\u2013STAT signaling pathway: a case-control study","volume":"21","author":"Harandi","year":"2024","journal-title":"Iran. J. Immunol."},{"issue":"12","key":"10.1016\/j.msard.2026.107265_bib0034","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","article-title":"Treatment of multiple sclerosis: a review","volume":"133","author":"Hauser","year":"2020","journal-title":"Am. J. Med."},{"issue":"8","key":"10.1016\/j.msard.2026.107265_bib0035","doi-asserted-by":"crossref","first-page":"16087","DOI":"10.3390\/ijms140816087","article-title":"MicroRNA expression changes during interferon-beta treatment in the peripheral blood of multiple sclerosis patients","volume":"14","author":"Hecker","year":"2013","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.msard.2026.107265_bib0036","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1212\/WNL.0b013e3181b04c98","article-title":"Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity","volume":"73","author":"Hesse","year":"2009","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2026.107265_bib0037","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.gene.2014.04.069","article-title":"miR-326 and miR-26a, two potential markers for diagnosis of relapse and remission phases in patient with relapsing-remitting multiple sclerosis","volume":"544","author":"Honardoost","year":"2014","journal-title":"Gene"},{"issue":"2","key":"10.1016\/j.msard.2026.107265_bib0038","first-page":"158","article-title":"The effect of interferon beta and Natalizumab on miR-20b expression in patients with relapsing-remitting multiple sclerosis is potentially mediated by modulation of the Jak-STAT signaling pathway: a case-control study","volume":"21","author":"Jafari Harandi","year":"2024","journal-title":"Iran. J. Immunol."},{"issue":"11","key":"10.1016\/j.msard.2026.107265_bib0039","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a032003","article-title":"Interferon \u03b2 for multiple sclerosis","volume":"8","author":"Jakimovski","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"3","key":"10.1016\/j.msard.2026.107265_bib0040","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000519777","article-title":"The effect of interferon-beta therapy on T-helper 17\/miR-326 and T-helper 1\/miR-29b-3p axis in relapsing-remitting multiple sclerosis patients","volume":"29","author":"Karimi","year":"2022","journal-title":"Neuroimmunomodulation"},{"issue":"4","key":"10.1016\/j.msard.2026.107265_bib0041","first-page":"416","article-title":"Comparison of expression levels of miR-29b-3p and miR-326 in T helper-1 and T helper-17 cells isolated from responsive and non-responsive relapsing-remitting multiple sclerosis patients treated with interferon-beta","volume":"19","author":"Karimi","year":"2020","journal-title":"Iran. J. Allergy Asthma Immunol."},{"key":"10.1016\/j.msard.2026.107265_bib0042","series-title":"Data Mining in Proteomics: From Standards to Applications","first-page":"291","article-title":"Cytoscape: software for visualization and analysis of biological networks","author":"Kohl","year":"2010"},{"issue":"14","key":"10.1016\/j.msard.2026.107265_bib0043","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1177\/13524585221108297","article-title":"EDSS 0 is not normal: multiple sclerosis disease burden below the clinical threshold","volume":"28","author":"Krieger","year":"2022","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2026.107265_bib0044","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420936166","article-title":"Sex effects across the lifespan in women with multiple sclerosis","volume":"13","author":"Krysko","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"2","key":"10.1016\/j.msard.2026.107265_bib0045","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3390\/cells9020482","article-title":"T helper cells: the modulators of inflammation in multiple sclerosis","volume":"9","author":"Kunkl","year":"2020","journal-title":"Cells"},{"issue":"13","key":"10.1016\/j.msard.2026.107265_bib0046","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.18632\/aging.102093","article-title":"Let-7f-5p suppresses Th17 differentiation via targeting STAT3 in multiple sclerosis","volume":"11","author":"Li","year":"2019","journal-title":"Aging"},{"key":"10.1016\/j.msard.2026.107265_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106348","article-title":"Women and multiple sclerosis: from gender medicine to precision medicine","volume":"96","author":"Lorefice","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107265_bib0048","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jneuroim.2016.01.009","article-title":"Dicer and microRNA expression in multiple sclerosis and response to interferon therapy","volume":"292","author":"Magner","year":"2016","journal-title":"J. Neuroimmunol."},{"issue":"2","key":"10.1016\/j.msard.2026.107265_bib0049","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3390\/cells10020330","article-title":"The microRNA let-7b-5p is negatively associated with inflammation and disease severity in multiple sclerosis","volume":"10","author":"Mandolesi","year":"2021","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.msard.2026.107265_bib0050","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/08830185.2020.1826474","article-title":"The role of microRNAs in multiple sclerosis","volume":"41","author":"Mansoor","year":"2022","journal-title":"Int. Rev. Immunol."},{"issue":"20","key":"10.1016\/j.msard.2026.107265_bib0051","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1001\/jama.2022.14236","article-title":"What is multiple sclerosis?","volume":"328","author":"Marcus","year":"2022","journal-title":"JAMA J. Am. Med. Assoc."},{"issue":"8","key":"10.1016\/j.msard.2026.107265_bib0052","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA J. Am. Med. Assoc."},{"issue":"1","key":"10.1016\/j.msard.2026.107265_bib0053","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1186\/s12913-014-0579-0","article-title":"PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews","volume":"14","author":"Methley","year":"2014","journal-title":"BMC Health Serv. Res."},{"key":"10.1016\/j.msard.2026.107265_bib0054","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2377-14-58","article-title":"Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis","volume":"14","author":"Meyer-Moock","year":"2014","journal-title":"BMC Neurol."},{"key":"10.1016\/j.msard.2026.107265_bib0055","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3389\/fimmu.2020.00947","article-title":"Interleukin-17 in chronic inflammatory neurological diseases","volume":"11","author":"Milovanovic","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2026.107265_bib0056","article-title":"Pharmacogenomics of multiple sclerosis: sieving treatment biomarkers from blood gene-expression profiles (PP-30)","volume":"2","author":"Mohaghegh","year":"2023","journal-title":"Neurol. Lett."},{"key":"10.1016\/j.msard.2026.107265_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102264","article-title":"Connection of miR-185 and miR-320a expression levels with response to interferon-beta in multiple sclerosis patients","volume":"44","author":"Mousavi","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"10","key":"10.1016\/j.msard.2026.107265_bib0058","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid. Synth."},{"key":"10.1016\/j.msard.2026.107265_bib0059","first-page":"372","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.msard.2026.107265_bib0060","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ibneur.2022.11.001","article-title":"MicroRNAs as a possible biomarker in the treatment of multiple sclerosis","volume":"13","author":"P\u00e9rez","year":"2022","journal-title":"IBRO Neurosci. Rep."},{"key":"10.1016\/j.msard.2026.107265_bib0061","article-title":"Multiple sclerosis: emerging epidemiological trends and redefining the clinical course","volume":"44","author":"Portaccio","year":"2024","journal-title":"Lancet Reg. Health"},{"issue":"1","key":"10.1016\/j.msard.2026.107265_bib0062","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.bbadis.2017.09.024","article-title":"Human miR-26a-5p regulates the glutamate transporter SLC1A1 (EAAT3) expression. Relevance in multiple sclerosis","volume":"1864","author":"Potenza","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.msard.2026.107265_bib0063","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2023.156235","article-title":"TNF-\u03b1\/STAT1\/CXCL10 mutual inflammatory axis that contributes to the pathogenesis of experimental models of multiple sclerosis: a promising signaling pathway for targeted therapies","volume":"168","author":"Rahmat-Zaie","year":"2023","journal-title":"Cytokine"},{"issue":"8","key":"10.1016\/j.msard.2026.107265_bib0064","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2217\/BMM.15.39","article-title":"Independent validation test of the vote-counting strategy used to rank biomarkers from published studies","volume":"9","author":"Rikke","year":"2015","journal-title":"Biomark. Med."},{"issue":"8","key":"10.1016\/j.msard.2026.107265_bib0065","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1080\/14737175.2021.1957832","article-title":"Beyond McDonald: updated perspectives on MRI diagnosis of multiple sclerosis","volume":"21","author":"Rovira","year":"2021","journal-title":"Expert Rev. Neurother."},{"issue":"17","key":"10.1016\/j.msard.2026.107265_bib0066","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gku631","article-title":"The multiMiR R package and database: integration of microRNA\u2013target interactions along with their disease and drug associations","volume":"42","author":"Ru","year":"2014","journal-title":"Nucleic Acids Res."},{"issue":"6","key":"10.1016\/j.msard.2026.107265_bib0067","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2217\/cer-2020-0267","article-title":"Efficacy classification of modern therapies in multiple sclerosis","volume":"10","author":"Samjoo","year":"2021","journal-title":"J. Comp. Eff. Res."},{"issue":"16","key":"10.1016\/j.msard.2026.107265_bib0068","doi-asserted-by":"crossref","first-page":"8751","DOI":"10.3390\/ijms25168751","article-title":"Primary progressive multiple sclerosis\u2013A key to understanding and managing disease progression","volume":"25","author":"Sempik","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.msard.2026.107265_bib0069","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jclinepi.2018.01.003","article-title":"Registration in the international prospective register of systematic reviews (PROSPERO) of systematic review protocols was associated with increased review quality","volume":"100","author":"Sideri","year":"2018","journal-title":"J. Clin. Epidemiol."},{"issue":"4","key":"10.1016\/j.msard.2026.107265_bib0070","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.4049\/jimmunol.1103171","article-title":"miR-29ab1 deficiency identifies a negative feedback loop controlling Th1 bias that is dysregulated in multiple sclerosis","volume":"189","author":"Smith","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.msard.2026.107265_bib0071","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577212","article-title":"miR-504 expression level is increased in multiple sclerosis patients responder to interferon-beta","volume":"342","author":"Tahmasebivand","year":"2020","journal-title":"J. Neuroimmunol."},{"issue":"2","key":"10.1016\/j.msard.2026.107265_bib0072","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.msard.2026.107265_bib0073","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41439-023-00260-x","article-title":"A novel DLG4 variant causes DLG4-related synaptopathy with intellectual regression","volume":"11","author":"Tokunaga","year":"2024","journal-title":"Hum. Genome Var."},{"issue":"4","key":"10.1016\/j.msard.2026.107265_bib0074","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.celrep.2019.09.020","article-title":"Oligodendrocyte intrinsic miR-27a controls myelination and remyelination","volume":"29","author":"Tripathi","year":"2019","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.msard.2026.107265_bib0075","doi-asserted-by":"crossref","first-page":"7536","DOI":"10.1038\/s41598-022-11444-w","article-title":"Multiple sclerosis genetic and non-genetic factors interact through the transient transcriptome","volume":"12","author":"Umeton","year":"2022","journal-title":"Sci. Rep."},{"issue":"14","key":"10.1016\/j.msard.2026.107265_bib0076","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS","volume":"26","author":"Walton","year":"2020","journal-title":"Mult. Scler. J."},{"issue":"9","key":"10.1016\/j.msard.2026.107265_bib0077","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024604","article-title":"Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis","volume":"6","author":"Waschbisch","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.msard.2026.107265_bib0078","doi-asserted-by":"crossref","unstructured":"Wickham H., Chang W., Wickham M.H. Package \u2018ggplot2.\u2019 Creat elegant data vis using Gramm graph version. 2016;2(1):1\u2013189.","DOI":"10.1007\/978-3-319-24277-4"},{"issue":"1","key":"10.1016\/j.msard.2026.107265_bib0079","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S1474-4422(22)00469-0","article-title":"Time to reconsider the classification of multiple sclerosis","volume":"22","author":"Yamamura","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2026.107265_bib0080","article-title":"Therapeutic advances in multiple sclerosis","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2026.107265_bib0081","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.717922","article-title":"Non-coding RNAs in the pathogenesis of multiple sclerosis","volume":"12","author":"Yousuf","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.msard.2026.107265_bib0082","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1441733","article-title":"MiRNA-based therapeutic potential in multiple sclerosis","volume":"15","author":"Zabalza","year":"2024","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.msard.2026.107265_bib0083","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1080\/08820139.2021.1887888","article-title":"Serum based miRNA as a diagnostic biomarker for Multiple sclerosis: a systematic review and meta-analysis","volume":"51","author":"Zailaie","year":"2022","journal-title":"Immunol. Investig."},{"issue":"2","key":"10.1016\/j.msard.2026.107265_bib0084","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/1744666X.2018.1426462","article-title":"Interferon \u03b2-1a and \u03b2-1b for patients with multiple sclerosis: updates to current knowledge","volume":"14","author":"Zettl","year":"2018","journal-title":"Expert Rev. Clin. Immunol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826003019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826003019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T03:43:57Z","timestamp":1780976637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826003019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":84,"alternative-id":["S2211034826003019"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107265","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uncovering the role of microRNAs in response to interferon-beta therapy among multiple sclerosis patients: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107265","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107265"}}